2022
Exports
$1.68BWorld Rnk 19 / 208
Flag Rnk 15 / 1206
2022
PRODUCT COMPLEXITY IN Vaccines, blood, antisera, toxins and cultures
1.38Rnk 75 / 1025
2022
Imports
$1.55BWorld Rnk 27 / 225
Flag Rnk 20 / 1210
2022
ECONOMIC COMPLEXITY of Hungary
1.38Rnk 14 / 133

About

Exports In 2022, Hungary exported $1.68B in Vaccines, blood, antisera, toxins and cultures, making it the 19th largest exporter of Vaccines, blood, antisera, toxins and cultures in the world. At the same year, Vaccines, blood, antisera, toxins and cultures was the 15th most exported product in Hungary. The main destination of Vaccines, blood, antisera, toxins and cultures exports from Hungary are: Germany ($327M), France ($191M), Poland ($125M), Czechia ($112M), and Italy ($106M).

The fastest growing export markets for Vaccines, blood, antisera, toxins and cultures of Hungary between 2021 and 2022 were Germany ($42.7M), Czechia ($32.5M), and Italy ($29.1M).

Imports In 2022, Hungary imported $1.55B in Vaccines, blood, antisera, toxins and cultures, becoming the 27th largest importer of Vaccines, blood, antisera, toxins and cultures in the world. At the same year, Vaccines, blood, antisera, toxins and cultures was the 20th most imported product in Hungary. Hungary imports Vaccines, blood, antisera, toxins and cultures primarily from: Germany ($350M), Netherlands ($332M), South Korea ($259M), Belgium ($154M), and United States ($96.2M).

The fastest growing import markets in Vaccines, blood, antisera, toxins and cultures for Hungary between 2021 and 2022 were Netherlands ($52M), Turkey ($43M), and Ireland ($31.9M).

Latest Trends

Oct 2024

Subnational Monthly Trade

View
Flow
Y-AXIS SCALE

For a full breakdown of trade patterns, visit the trend explorer or the product in country profile.

The following visualization shows the latest trends on Vaccines, blood, antisera, toxins and cultures. Countries are shown based on data availability.

* Using January 2020 exchange rates when trade data is reported in local currency.

Explore Latest Trends

Subscribe today to OEC pro and access the latest data

Sign Up

Historical Data

Trade Balance

Color
EXPORTS (2022)$1.68B
IMPORTS (2022)$1.55B
NET TRADE (2022)$132M

In 2022, Hungary exported $1.68B in Vaccines, blood, antisera, toxins and cultures. The main destinations of Hungary exports on Vaccines, blood, antisera, toxins and cultures were Germany ($327M), France ($191M), Poland ($125M), Czechia ($112M), and Italy ($106M).

In 2022, Hungary imported $1.55B in Vaccines, blood, antisera, toxins and cultures, mainly from Germany ($350M), Netherlands ($332M), South Korea ($259M), Belgium ($154M), and United States ($96.2M).

Explore Visualizations

Export Destinations (2022)

Import Origins (2022)

Market Growth

Flow
THE FASTEST GROWING Vaccines, blood, antisera, toxins and cultures EXPORT MARKETS FOR Hungary WERE (2021 - 2022):
Germany$42.7M (15%)
Czechia$32.5M (40.8%)
Italy$29.1M (37.6%)
THE FASTEST DECLINING MARKETS FOR THE EXPORT OF Vaccines, blood, antisera, toxins and cultures BY Hungary WERE (2021 - 2022):
United States-$113M (-58.8%)
United Kingdom-$60.7M (-90.8%)
Austria-$36.7M (-54.1%)

Change in Exports by Market (2021 - 2022)

Market Concentration

View
Flow
Type
In 2022, Hungary's main exporting competitors in Vaccines, blood, antisera, toxins and cultures were:
In 2022, Hungary's main importing competitors in Vaccines, blood, antisera, toxins and cultures were:

Explore Visualizations

Trade Value of Vaccines, blood, antisera, toxins and cultures by Exporters

Potential Exports

Potential Exports

Flow
View
TOP EXPORT POTENTIALGermany+ $118M
TOP IMPORT POTENTIALGermany+ $71.8M

Vaccines, blood, antisera, toxins and cultures’s highest export potential is Germany. With an export gap of $118M.   Vaccines, blood, antisera, toxins and cultures’s highest import potential is Germany with an import gap of $71.8M.

See methodology.

Subscribe today to OEC pro and access the latest data

Sign Up

Have questions, comments, or concerns?
Send us an e-mail: support@oec.world
Follow @OECtoday on
Created, Designed, and Developed by:
In collaboration with